Skip to main content

Advertisement

SpringerLink
Log in

Management of bone metastases in breast cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Patients with advanced breast cancer who develop bone metastases suffer an ongoing risk of skeletal complications that can have a significant impact on their quality of life (QoL). These complications include bone pain, pathologic fractures, spinal cord compression, and hypercalcemia of malignancy (HCM), a potentially life-threatening condition. Treatment options include radiotherapy to palliate bone pain and/ or prevent impending fracture, orthopedic surgery to prevent or repair fractures, analgesics, and bisphosphonates, which can significantly reduce the risk of skeletal complications and delay their onset. Of the known bisphosphonates, zoledronic acid is the most potent. Since its regulatory approval in the United States and Europe in 2001, zoledronic acid (4 mg by 15-minute infusion) has become widely used and has replaced pamidronate (90 mg by 2-hour infusion) as the standard of care for treating bone metastases from breast cancer and bone lesions from multiple myeloma. Zoledronic acid has also demonstrated significant long-term benefits in randomized trials in prostate cancer and other solid tumors, whereas other bisphosphonates have failed. In long-term, phase III clinical testing, zoledronic acid provided significant treatment benefits beyond those of pamidronate in patients with breast cancer and demonstrated a safety profile comparable with pamidronate. Therefore, zoledronic acid is now recommended from the first diagnosis of bone metastasis. Other intravenous bisphosphonates include clodronate and ibandronate. Both are approved in Europe, but their efficacy relative to pamidronate and zoledronic acid is not known.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ferlay J, Bray F, Pisani P, Parkin DM: Estimating the world cancer burden:Globocan 2000. Int J Cancer 2001, 94:153–156. Accessible at http://www-dep.iarc.fr/ globocan/cdrom.htm.

    Article  PubMed  Google Scholar 

  2. Coleman RE:Metastatic bone disease:clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165–176. This review explains the identification and characterization of bone lesions, available therapies, and possible complications

    Article  PubMed  CAS  Google Scholar 

  3. Theriault RL, Lipton A, Hortobagyi GN, et al.:Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions:a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999, 17:846–854.

    PubMed  CAS  Google Scholar 

  4. Lipton A, Theriault RL, Hortobagyi GN, et al.:Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases:long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88:1082–1090. This trial established the long-term safety and efficacy of pamidronate in patients with osteolytic lesions from breast cancer.

    Article  PubMed  CAS  Google Scholar 

  5. Major PP, Cook R:Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol 2002, 25(Suppl 1):10–18. This review article summarizes the challenges of assessing skeletal morbidity in patients with malignant bone disease and the respective merit of clinical trial endpoints in this setting. The results of clinical trials of bisphosphonates in patients with breast or prostate cancer are critically analyzed.

    Article  Google Scholar 

  6. van der Linden YM, Kroon HM, Dijkstra SP, et al.:Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions:results from a randomised trial. Radiother Oncol 2003, 69:21–31.

    Article  PubMed  Google Scholar 

  7. Peh WC, Gilula LA:Percutaneous vertebroplasty:indications, contraindications, and technique. Br J Radiol 2003, 76:69–75.

    Article  PubMed  CAS  Google Scholar 

  8. Serafini AN:Therapy of metastatic bone pain. J Nucl Med 2001, 42:895–906. This review article provides a broad overview of therapies available for the palliative care of patients with bone pain from cancer and provides more specific information on radiotherapy options.

    PubMed  CAS  Google Scholar 

  9. Jereczek-Fossa BA, Marsiglia HR, Orecchia R:Radiotherapy-related fatigue. Crit Rev Oncol Hematol 2002, 41:317–325.

    Article  PubMed  Google Scholar 

  10. Body JJ:Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003, 97(Suppl):859–865.

    Article  PubMed  Google Scholar 

  11. Lipton A:Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 2003, 8:469–488.

    Article  PubMed  CAS  Google Scholar 

  12. Green JR, Clezardin P:Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002, 25(Suppl 1):3–9.

    Article  Google Scholar 

  13. Luckman SP, Hughes DE, Coxon FP, et al.:Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581–589.

    Article  PubMed  CAS  Google Scholar 

  14. Berenson JR, Hillner BE, Kyle RA, et al.:American Society of Clinical Oncology clinical practice guidelines:the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002, 20:3719–3736.

    Article  PubMed  Google Scholar 

  15. Hillner BE, Ingle JN, Chelbowski RT, et al.:American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042–4057. This article summarizes the updated consensus guidelines established by the American Society of Clinical Oncology for the use of bisphosphonates to maintain bone health and prevent skeletal complications in patients with breast cancer.

    Article  PubMed  CAS  Google Scholar 

  16. Johnson JR, Williams G, Pazdur R:End points and US Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003, 21:1404–1411.

    Article  PubMed  Google Scholar 

  17. Lipton A, Small E, Saad F, et al.:The new bisphosphonate, ZOMETA (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions:a comparison to pamidronate. Cancer Invest 2002, 20(Suppl 2):45–54. This review and analysis of phase III clinical trial data for zoledronic acid in patients with malignant bone disease summarizes the broad efficacy of zoledronic acid in patients with osteolytic, osteoblastic, and mixed-bone lesions secondary to a broad range of primary-tumor types.

    Article  PubMed  CAS  Google Scholar 

  18. Rosen LS, Gordon D, Tchekmedyian S, et al.:Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150–3157.

    Article  PubMed  CAS  Google Scholar 

  19. Rosen LS, Gordon D, Kaminski M, et al.:Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer:a randomized, doubleblind, multicenter, comparative trial. Cancer 2003, 98:1735–1744. This 2-year extension of the 12-month core trial established that zoledronic acid is more effective than pamidronate in reducing the risk of skeletal morbidity in the overall population of patients with breast cancer or multiple myeloma and in the subset of patients with breast cancer. Zoledronic acid was safe for long-term use in this setting.

    Article  PubMed  CAS  Google Scholar 

  20. Body JJ, Diel IJ, Lichinitser MR, et al.:Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003, 14:1399–1405.

    Article  PubMed  Google Scholar 

  21. Rosen LS, Gordon DH, Dugan W Jr, et al.:Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004, 100:36–43. This analysis of the 13-month data from the phase III clinical trial comparing zoledronic acid with pamidronate in patients with breast cancer reveals that zoledronic acid has significantly greater efficacy compared with pamidronate in patients with at least one primarily osteolytic bone lesion.

    Article  PubMed  CAS  Google Scholar 

  22. Andersen PK, Gill RD:Cox’s regression model for counting processes:a large sample study. Ann Stat 1982, 10:1100–1120.

    Google Scholar 

  23. Maxwell C, Swift R, Goode M, et al.:Advances in supportive care of patients with cancer and bone metastases:nursing implications of zoledronic acid. Clin J Oncol Nurs 2003, 7:403–408.

    PubMed  Google Scholar 

  24. Hortobagyi GN, Theriault RL, Lipton A, et al.:Longterm prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998, 16:2038–2044.

    PubMed  CAS  Google Scholar 

  25. Aredia [package insert]. East Hanover, NJ:Novartis Pharmaceuticals Corporation; 2002.

  26. Hillner BE, Weeks JC, Desch CE, Smith TJ:Pamidronate in prevention of bone complications in metastatic breast cancer:a cost-effectiveness analysis. J Clin Oncol 2000, 18:72–79.

    PubMed  CAS  Google Scholar 

  27. Hillner BE, Ingle JN, Berenson JR, et al.:American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000, 18:1378–1391. This article summarizes the consensus guidelines established by the American Society of Clinical Oncology for the use of bisphosphonates in patients with breast cancer.

    PubMed  CAS  Google Scholar 

  28. Pavlakis N, Stockler M:Bisphosphonates for breast cancer [review]. Cochrane Database Syst Rev 2002:CD003474. This analysis supports the use of bisphosphonates for palliative therapy in patients with bone metastases from breast cancer.

  29. Rosen LS, Gordon D, Kaminski M, et al.:Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma:a phase III, doubleblind, comparative trial. Cancer J 2001, 7:377–387. This 13-month report of a large-scale randomized clinical trial in patients with multiple myeloma or breast cancer reports that zoledronic acid has comparable safety and efficacy with that of pamidronate, and that zoledronic acid may provide additional benefits in some endpoints and patient populations.

    PubMed  CAS  Google Scholar 

  30. Coleman R, Cook R, Major P, et al.:Why is zoledronic acid superior to pamidronate for bone metastases from breast cancer but equivalent in multiple myeloma? [poster]. Presented at 39th Annual Meeting of the American Society of Clincal Oncology. Chicago, Illinois; May 31-June 2, 2003.

  31. Coleman R, Rosen L, Study 010 investigators:Zoledronic acid has long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer [abstract]. To be presented at:4th European Breast Cancer Conference. Hamburg, Germany:March 16–20, 2004.

  32. Major P, Lortholary A, Hon J, et al.:Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19:558–567. This pooled analysis of two randomized trials established that zoledronic acid is superior to pamidronate for treating patients with hypercalcemia of malignancy.

    PubMed  CAS  Google Scholar 

  33. Wardley AM, Davidson N, Barrett-Lee P, et al.:Zoledronic acid significantly improves pain scores in patients with skeletal metastases secondary to breast cancer:analysis of home versus hospital administration [abstract]. Proc Am Soc Clin Oncol 2003, 22:749.

    Google Scholar 

  34. Zometa [package insert]. East Hanover, NJ:Novartis Pharmaceuticals Corporation; 2003.

  35. DesHarnais Castel L, Bajwa K, Markle JP, et al.:A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001, 9:545–551.

    Article  Google Scholar 

  36. Bondronat [Summary of Product Characteristics]. Hertfordshire, England, United Kingdom:Roche Registration Limited. 2003.

  37. Lyubimova NV, Kushlinsky NE, Lichinitser MR, Schlosser K:Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease. Clin Drug Invest 2003, 23:707–716.

    Article  CAS  Google Scholar 

  38. Gnant M, Hausmaninger H, Samonigg H, et al.:Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer:results of a randomized multicenter trial [abstract]. Presented at the 25th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas; December 11–14, 2002.

  39. McCloskey EV, Dunn JA, Kanis JA, et al.:Long-term follow-up of a prospective, double-blind, placebocontrolled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001, 113:1035–1043.

    Article  PubMed  CAS  Google Scholar 

  40. Saad F, Lipton A, Colombo-Berra A, et al.:Zometa (zoledronic acid) is effective in preventing and delaying skeletal events in patients with bone metastases secondary to urologic malignancies [abstract]. Presented at Quebec Urological Association Meeting. Montreal, Quebec, Canada; November 15–17, 2002.

  41. Diel IJ, Solomayer EF, Costa SD, et al.:Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357–363.

    Article  PubMed  CAS  Google Scholar 

  42. Saarto T, Blomqvist C, Virkkunen P, Elomaa I:Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients:5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10–17.

    PubMed  CAS  Google Scholar 

  43. Powles T, Paterson S, Kanis JA, et al.:Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219–3224.

    Article  PubMed  CAS  Google Scholar 

  44. Yoneda T, Hashimoto N, Hiraga T:Bisphosphonate actions on cancer. Calcif Tissue Int 2003, 73:315–318.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Milton S. Hershey Medical Center, College of Medicine, Penn State University, 500 University Drive, 17033, Hershey, PA, USA

    Allan Lipton (MD)

Authors
  1. Allan Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lipton, A. Management of bone metastases in breast cancer. Curr. Treat. Options in Oncol. 6, 161–171 (2005). https://doi.org/10.1007/s11864-005-0023-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0023-0

Keywords

Search

Navigation